174 related articles for article (PubMed ID: 28251109)
1. Effect of hydroalcoholic extract of
Sarkari B; Mohseni M; Moein MR; Shahriarirad R; Asgari Q
Int J Appl Basic Med Res; 2017; 7(1):53-56. PubMed ID: 28251109
[TBL] [Abstract][Full Text] [Related]
2. Combined therapy with adipose tissue-derived mesenchymal stromal cells and meglumine antimoniate controls lesion development and parasite load in murine cutaneous leishmaniasis caused by Leishmania amazonensis.
Ramos TD; Silva JD; da Fonseca-Martins AM; da Silveira Pratti JE; Firmino-Cruz L; Maciel-Oliveira D; Dos-Santos JS; Tenorio JIN; de Araujo AF; Freire-de-Lima CG; Diaz BL; Cruz FF; Rocco PRM; de Matos Guedes HL
Stem Cell Res Ther; 2020 Aug; 11(1):374. PubMed ID: 32867857
[TBL] [Abstract][Full Text] [Related]
3. Meglumine Antimoniate (Glucantime) Causes Oxidative Stress-Derived DNA Damage in BALB/c Mice Infected by Leishmania (Leishmania) infantum.
Moreira VR; de Jesus LCL; Soares RP; Silva LDM; Pinto BAS; Melo MN; Paes AMA; Pereira SRF
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28320726
[TBL] [Abstract][Full Text] [Related]
4. Comparative histological and immunohistochemical changes of dry type cutaneous leishmaniasis after administration of meglumine antimoniate, imiquimod or combination therapy.
Shamsi Meymandi S; Javadi A; Dabiri S; Shamsi Meymandi M; Nadji M
Arch Iran Med; 2011 Jul; 14(4):238-43. PubMed ID: 21726098
[TBL] [Abstract][Full Text] [Related]
5. Use of topical liposomes containing meglumine antimoniate (Glucantime) for the treatment of L. major lesion in BALB/c mice.
Kalat SA; Khamesipour A; Bavarsad N; Fallah M; Khashayarmanesh Z; Feizi E; Neghabi K; Abbasi A; Jaafari MR
Exp Parasitol; 2014 Aug; 143():5-10. PubMed ID: 24780938
[TBL] [Abstract][Full Text] [Related]
6. Topical application of ozonated sunflower oil accelerates the healing of lesions of cutaneous leishmaniasis in mice under meglumine antimoniate treatment.
Pivotto AP; de Souza Lima LB; Michelon A; Ferreira CZP; Gandra RF; Ayala TS; Menolli RA
Med Microbiol Immunol; 2024 Mar; 213(1):4. PubMed ID: 38532203
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Thymus vulgaris (Thyme), Achillea millefolium (Yarrow) and propolis hydroalcoholic extracts versus systemic glucantime in the treatment of cutaneous leishmaniasis in balb/c mice.
Nilforoushzadeh MA; Shirani-Bidabadi L; Zolfaghari-Baghbaderani A; Saberi S; Siadat AH; Mahmoudi M
J Vector Borne Dis; 2008 Dec; 45(4):301-6. PubMed ID: 19248657
[TBL] [Abstract][Full Text] [Related]
8. A trial of immunotherapy against Leishmania amazonensis infection in vitro and in vivo with Z-100, a polysaccharide obtained from Mycobacterium tuberculosis, alone or combined with meglumine antimoniate.
Barroso PA; Marco JD; Calvopina M; Kato H; Korenaga M; Hashiguchi Y
J Antimicrob Chemother; 2007 Jun; 59(6):1123-9. PubMed ID: 17439977
[TBL] [Abstract][Full Text] [Related]
9. Clinical efficacy of intramuscular meglumine antimoniate alone and in combination with intralesional meglumine antimoniate in the treatment of old world cutaneous leishmaniasis.
Munir A; Janjua SA; Hussain I
Acta Dermatovenerol Croat; 2008; 16(2):60-4. PubMed ID: 18541100
[TBL] [Abstract][Full Text] [Related]
10. The activity of encapsulated meglumine antimoniate in stearylamine-bearing liposomes against cutaneous leishmaniasis in BALB/c mice.
Moosavian SA; Fallah M; Jaafari MR
Exp Parasitol; 2019 May; 200():30-35. PubMed ID: 30898544
[TBL] [Abstract][Full Text] [Related]
11. Combined suboptimal schedules of topical paromomycin, meglumine antimoniate and miltefosine to treat experimental infection caused by Leishmania (Viannia) braziliensis.
de Morais-Teixeira E; Aguiar MG; Soares de Souza Lima B; Ferreira LA; Rabello A
J Antimicrob Chemother; 2015 Dec; 70(12):3283-90. PubMed ID: 26346991
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic effect of sodium selenite and zinc sulphate as supplementary with meglumine antimoniate( glucantime®) against cutaneous leishmaniasis in BALB/c mice.
Sorkhroodi FZ; Naeini AA; Ramazani AZ; Ghazvini MA; Mohebali M; Keshavarz S
Iran J Parasitol; 2010 Sep; 5(3):11-9. PubMed ID: 22347250
[TBL] [Abstract][Full Text] [Related]
13. Naloxone Effects Against Cutaneous Leishmaniasis Caused by
Azizi H; Mahdavinik E; Hataminejad M; Khamesipour A; Montazeri S
Infect Disord Drug Targets; 2023; 23(6):e020623217598. PubMed ID: 37278044
[TBL] [Abstract][Full Text] [Related]
14. Comparative study of the efficacy of combined cryotherapy and intralesional meglumine antimoniate (Glucantime) vs. cryotherapy and intralesional meglumine antimoniate (Glucantime) alone for the treatment of cutaneous leishmaniasis.
Asilian A; Sadeghinia A; Faghihi G; Momeni A
Int J Dermatol; 2004 Apr; 43(4):281-3. PubMed ID: 15090013
[TBL] [Abstract][Full Text] [Related]
15. Leishmania RNA virus 2 (LRV2) exacerbates dermal lesions caused by Leishmania major and comparatively unresponsive to meglumine antimoniate treatment.
Saberi R; Fakhar M; Hajjaran H; Abbaszadeh Afshar MJ; Mohebali M; Hezarjaribi HZ; Moghadam Y; Sharbatkhori M
Exp Parasitol; 2022 Oct; 241():108340. PubMed ID: 35932908
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo antileishmanial effects of
Alizadegan F; Aghaei M; Kumar SJ; Saadatmand M; Kumar SA
J Parasit Dis; 2023 Sep; 47(3):683-688. PubMed ID: 37520187
[TBL] [Abstract][Full Text] [Related]
17. Decreased sensitivity to meglumine antimoniate (Glucantime) of Leishmania infantum isolated from dogs after several courses of drug treatment.
Gramiccia M; Gradoni L; Orsini S
Ann Trop Med Parasitol; 1992 Dec; 86(6):613-20. PubMed ID: 1304703
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic Potential of Green Synthesized Copper Nanoparticles Alone or Combined with Meglumine Antimoniate (Glucantime
Albalawi AE; Abdel-Shafy S; Khudair Khalaf A; Alanazi AD; Baharvand P; Ebrahimi K; Mahmoudvand H
Nanomaterials (Basel); 2021 Mar; 11(4):. PubMed ID: 33807273
[TBL] [Abstract][Full Text] [Related]
19. Role of imiquimod and parenteral meglumine antimoniate in the initial treatment of cutaneous leishmaniasis.
Arevalo I; Tulliano G; Quispe A; Spaeth G; Matlashewski G; Llanos-Cuentas A; Pollack H
Clin Infect Dis; 2007 Jun; 44(12):1549-54. PubMed ID: 17516397
[TBL] [Abstract][Full Text] [Related]
20. Effects of combined therapy with silymarin and glucantime on leishmaniasis induced by Leishmania major in BALB/c mice.
Jabini R; Jaafari MR; Vahdati Hasani F; Ghazizadeh F; Khamesipour A; Karimi G
Drug Res (Stuttg); 2015 Mar; 65(3):119-24. PubMed ID: 24623031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
